Advantages at a glance
- Pools of 14 peptides
- Purity: Each peptide ESI-MS checked, pool is purified by solid phase extraction.
- Amount: 25µg each peptide (350µg for complete pool)
- UniProt ID: P0DTC2
- Free shipping
- Shipping within 24h
- 30 days money back guarantee
- Purchase comfortable on account
Product information "Epsilon Variant (B.1.427/B.1.429) Peptide Pool SARS-CoV-2 (Spike Glycoprotein) "
Peptide pool with 14 peptides that covers all mutations in the Spike Glycoprotein derived from the epsilon variant B.1.427/B.1.429 of SARS-CoV-2.
Possilbe applications: T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response.
Each peptide is purified by solid phase extraction and checked on its purity by ESI-MS.
This peptide pool is supplied lyophilized as trifluoroacetate salt.
Peptide sequences included (15 nmol (approx. 25ug)/peptide for stimulation of 2.5 x 10E8 cells):
MFVFLVLLPLVSIQC AVLYQGVNCTEVPVA LVLLPLVSIQCVNLT QGVNCTEVPVAIHAD PLVSIQCVNLTTRTQ IQCVNLTTRTQLPPA LGVYYHKNNKSCMES YHKNNKSCMESEFRV NKSCMESEFRVYSSA LDSKVGGNYNYRYRL VGGNYNYRYRLFRKS YNYRYRLFRKSNLKP GTNTSNQVAVLYQGV SNQVAVLYQGVNCTE
Dissolve in a minimum amount of pure DMSO (approx. 40µL) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological system.
Protein ID: P0DTC2 (swiss prot)
| Gene: | S | |
| No Peptides: | 80 peptides | |
| Amount Peptide: | 25 µg | |
| Amount Aliquote: | 2,0 mg | |
| Uniprot Id: | P0DTC2 | |
| Solubility: | Dissolve in a minimum amount of pure DMSO (approx. 40μl) and dilute with water to the desired concentration. Please pay attention that the final concentration of DMSO must be below 1% (v/v) to avoid toxicity in the biological | |
| Storage: | Store at -20°C | |
| Delivery: | 2-3 days | |
| Purity: | Each peptide ESI-MS checked, pool is purified by solid phase extraction | |
| Counter Ion: | TFA | |
| Protein: | Spike glycoprotein | |
| Species: | Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) | |
| Application : | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response | |
| Indication : | Covid-19, Infection, Respiratory infection |
Application:
T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response.Source:
syntheticClassification:
Documents:
Product descriptionAccessory Items
This peptide pool of the omicron variant of SARS-CoV-2 (315 peptides, delivered in two subpools of 158 & 157 peptides) that covers the whole spike glycoprotein with all mutations. Possilbe applications: T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response. Each peptide is purified by solid phase extraction and checked on its purity by ESI-MS.The peptides of this product are supplied lyophilized as trifluoro acetate salts. Peptide Scan 15/11Length: 1270 amino acidsMFVFLVLLPLVSSQCVNLTTRTQLPPAYTNSFTRGVYYPDKVFRSSVLHSTQDLFLPFFSNVTWFHVISGTNGTKRFDNPVLPFNDGVYFASIEKSNIIRGWIFGTTLDSKTQSLLIVNNATNVVIKVCEFQFCNDPFLDHKNNKSWMESEFRVYSSANNCTFEYVSQPFLMDLEGKQGNFKNLREFVFKNIDGYFKIYSKHTPIIVREPEDLPQGFSALEPLVDLPIGINITRFQTLLALHRSYLTPGDSSSGWTAGAAAYYVGYLQPRTFLLKYNENGTITDAVDCALDPLSETKCTLKSFTVEKGIYQTSNFRVQPTESIVRFPNITNLCPFDEVFNATRFASVYAWNRKRISNCVADYSVLYNLAPFFTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGNIADYNYKLPDDFTGCVIAWNSNKLDSKVSGNYNYLYRLFRKSNLKPFERDISTEIYQAGNKPCNGVAGFNCYFPLKSYGFQPTYGVGHQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKCVNFNFNGLKGTGVLTESNKKFLPFQQFGRDIADTTDAVRDPQTLEILDITPCSFGGVSVITPGTNTSNQVAVLYQGVNCTEVPVAIHADQLTPTWRVYSTGSNVFQTRAGCLIGAEYVNNSYECDIPIGAGICASYQTQTKSHRRARSVASQSIIAYTMSLGAENSVAYSNNSIAIPTNFTISVTTEILPVSMTKTSVDCTMYICGDSTECSNLLLQYGSFCTQLKRALTGIAVEQDKNTQEVFAQVKQIYKTPPIKYFGGFNFSQILPDPSKPSKRSFIEDLLFNKVTLADAGFIKQYGDCLGDIAARDLICAQKFKGLTVLPPLLTDEMIAQYTSALLAGTITSGWTFGAGAALQIPFAMQMAYRFNGIGVTQNVLYENQKLIANQFNSAIGKIQDSLSSTASALGKLQDVVNHNAQALNTLVKQLSSKFGAISSVLNDIFSRLDKVEAEVQIDRLITGRLQSLQTYVTQQLIRAAEIRASANLAATKMSECVLGQSKRVDFCGKGYHLMSFPQSAPHGVVFLHVTYVPAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTFVSGNCDVVIGIVNNTVYDPLQPELDSFKEELDKYFKNHTSPDVDLGDISGINASVVNIQKEIDRLNEVAKNLNESLIDLQELGKYEQYIKWPWYIWLGFIAGLIAIVMVTIMLCCMTSCCSCLKGCCSCGSCCKFDEDDSEPVLKGVKLHYT